摘要
目的讨论普米克令舒联合西咪替丁辅助治疗小儿毛细支气管炎对病程的影响。方法将60例于2017年3月—2020年3月期间该院收治的小儿毛细支气管炎患儿作为研究对象,以等额随机法分为对照组(实施常规治疗+普米克令舒治疗方案)与研究组(实施常规治疗+普米克令舒+西咪替丁治疗方案),各30例,观察指标:疗效;临床症状恢复时间及住院时间;不良反应;治疗后免疫指标。结果实施研究组治疗方案后患儿治疗有效率的96.67%明显高于实施对照组治疗方案后患儿有效率的66.67%(χ^(2)=9.016,P<0.05)。实施研究组治疗方案后患儿的临床症状恢复时间及住院时间指标均明显短于实施对照组治疗方案后患儿的临床症状恢复时间及住院时间(哮鸣音消失:t=5.056、气促缓解:t=4.712、湿啰音消失:t=5.664、咳嗽消失:t=5.187、平均住院时间:t=5.055,P<0.001)。实施研究组治疗方案后患儿的CD3+、CD4+、CD8+免疫指标均明显高于对照组(CD3+:t=6.013、CD4+:t=2.046、CD8+:t=3.858,P<0.05)。两组患儿治疗期间均未出现明显不良反应。结论普米克令舒联合西咪替丁治疗小儿毛细支气管炎病症的疗效明显,利于促使患儿症状及体征的恢复,提高其机体免疫力,且无明显副作用,值得推广。
Objective To discuss the effect of pulmicort and cimetidine in adjuvant treatment of bronchiolitis in children on the course of the disease. Methods Sixty children with bronchiolitis in children who were admitted to the hospital from March 2017 to March 2020 were taken as the research subjects, and randomly divided into the control group(conventional treatment + Pulmicort Resin treatment plan) and the study. Group(conventional treatment + Pulmicort Resin + Cimetidine treatment program), 30 cases in each group, observation indicators: curative effect;clinical symptoms recovery time and hospital stay;adverse reactions;immune indicators after treatment. Results The effective rate of 96.67% of the children in the study group was significantly higher than the 66.67% of the children in the control group(χ^(2)=9.016 P<0.05). The clinical symptoms recovery time and hospitalization time indicators of the children after the implementation of the treatment plan of the study group were significantly shorter than the clinical symptoms recovery time and hospitalization time of the children after the implementation of the treatment plan of the control group(wheezing disappeared : t =5.056, shortness of breath was relieved: t=4.712, disappearance of wet rales: t=5.664, disappearance of cough: t=5.187, average hospital stay: t=5.055, P<0.001). The CD3+, CD4+, and CD8+ immune indexes of the children in the study group were significantly higher than those in the control group after the treatment program was implemented(CD3+ :t=6.013, CD4+:t=2.046, CD8+:t=3.858,P<0.05). There were no obvious adverse reactions during the treatment of the two groups of children. Conclusion Pulmicort Retinol combined with cimetidine is effective in treating children with bronchiolitis. It is beneficial to promote the recovery of children’s symptoms and signs, improve their immunity, and has no obvious side effects. It is worthy of promotion.
作者
张海燕
ZHANG Hai-yan(Department of Pediatrics,Rudong County People's Hospital,Nantong,Jiangsu Province,226400 China)
出处
《世界复合医学》
2021年第2期163-165,共3页
World Journal of Complex Medicine
